Trastuzumab deruxtecan (T-DXd) sensitivity in various levels of HER2 expressing gastric cancer cells.

被引：0
|
作者：
Yu, Seo Young [1 ]
Park, Juin [2 ]
Kwon, Woo Sun [2 ]
Jeong, Inhye [2 ]
Kang, Sun Kyoung [2 ]
Bae, Hyun Joo [1 ]
Kim, Tae Soo [2 ]
Chung, Hyun Cheol [3 ]
Rha, Sun Young [3 ]
机构：
[1] Yonsei Univ, Coll Med, Brain Korea 21 PLUS Project Med Sci, Seoul, South Korea
[2] Yonsei Univ, Songdang Inst Canc Res, Coll Med, Seoul, South Korea
[3] Yonsei Univ Hlth Syst, Div Med Oncol, Dept Internal Med, Yonsei Canc Ctr, Seoul, South Korea
来源：
CANCER RESEARCH | 2021年 / 81卷 / 13期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
945
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Population pharmacokinetics of trastuzumab deruxtecan (T-DXd) in subjects with HER2-mutant and HER2-overexpressing non-small cell lung cancer (NSCLC)
    Khatri, Amit
    Cobbina, Enoch
    Cheng, Shen
    Abutarif, Malaz
    Garimella, Tushar
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [32] T-DXd for HER2-low expressing cases breast cancer at our hospital
    Noguchi, E.
    Shimizu, Y.
    Nogami, M.
    Tsukada, H.
    Natori, K.
    Aoyama, K.
    Akashi-Tanaka, S.
    ANNALS OF ONCOLOGY, 2024, 35 : S1395 - S1395
  • [33] Fam-Trastuzumab Deruxtecan in HER2/Neu-Expressing Serous Endometrial Cancer
    Rose, Peter G.
    Kelley, Johanna A.
    Feldman, Myra
    Krivanek, Kevin
    JCO PRECISION ONCOLOGY, 2023, 7
  • [34] A phase 2 trial of trastuzumab deruxtecan (T-DXd, DS-8201) in patients with HER2-positive, unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma
    Fuchs, C.
    Shahidi, J.
    Mathew, L.
    Qin, A.
    Van Cutsem, E.
    ANNALS OF ONCOLOGY, 2020, 31 : S150 - S150
  • [35] Lovastatin enhances the antiproliferative effect of trastuzumab in HER2 over expressing breast cancer cells.
    Halaweh, O. M.
    Lobocki, C.
    Dumasia, L.
    Drelichman, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 111S - 111S
  • [36] Durable clinical and radiographic responses in a series of patients with HER2+Breast Cancer (BC) Leptomeningeal Disease (LMD) treated with trastuzumab deruxtecan (T-DXd).
    Alder, Laura
    Trapani, Dario
    Van Swearingen, Amanda
    Khasraw, Mustafa
    Anders, Carey
    Lin, Nancy
    Sammons, Sarah
    CANCER RESEARCH, 2022, 82 (12)
  • [37] Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing head and neck tumors: Outcomes from DESTINY-PanTumor02 (DP-02)
    Meric-Bernstam, Funda
    Kim, Seung Tae
    Parinyanitikul, Napa
    Moreno, Alberto
    Lin, Chia-Chi
    Gornastolev, Dmitry
    Chindaprasirt, Jarin
    Lugowska, Iwona A.
    Stroyakovskiy, Daniil
    Jassem, Jacek
    Harrison, Michelle L.
    Ostwal, Vikas S.
    Michelini, Flavia
    Jung, Lindsey
    Kuptsova-Clarkson, Nataliya
    Puvvada, Soham D.
    Gan, Hui Kong
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [38] Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing biliary tract cancer (BTC) and pancreatic cancer (PC): Outcomes from DESTINY-PanTumor02 (DP-02)
    Oh, Do-Youn
    Lugowska, Iwona A.
    Stroyakovskiy, Daniil
    Jung, Kyung Hae
    Dumas, Olivier
    Penkov, Konstantin
    Dechaphunkul, Arunee
    Oaknin, Ana
    Kim, Seung Tae
    Starling, Naureen
    Chewaskulyong, Busyamas
    Charonpongsuntorn, Chanchai
    Doroshow, Deborah Blythe
    Hsiao, Sheng-Yen
    Hung, Yi-Ping
    Jung, Lindsey
    Kuptsova-Clarkson, Nataliya
    Michelini, Flavia
    Puvvada, Soham D.
    Meric-Bernstam, Funda
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [39] Co- occurring HER2 and PD-L1 expression in patients with HER2-positive trastuzumab-refractory gastric cancer (GC)/gastroesophageal junction adenocarcinoma (GEJA): Biomarker analysis from the trastuzumab deruxtecan (T-DXd) DESTINY-Gastric03 trial
    Janjigian, Y.
    Rha, S.
    Oh, D.
    Diez Garcia, M.
    van Laarhoven, H.
    Chao, Y.
    Di Bartolomeo, M.
    Mohammad, N. Haj
    Zhong, W.
    Croydon, E.
    Cecchi, F.
    Lee, J.
    ANNALS OF ONCOLOGY, 2022, 33 : S358 - S359
  • [40] HER2 persistence after treatment with T-DXd in breast and gastrointestinal cancers
    Drago, Joshua Z.
    Pareja, Fresia
    Jhaveri, Komal L.
    Walsh, Elaine M.
    Ku, Geoffrey Yuyat
    Maron, Steven Brad
    Janjigian, Yelena Y.
    Robson, Mark E.
    Reis-Filho, Jorge S.
    Modi, Shanu
    Razavi, Pedram
    Chandarlapaty, Sarat
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345